Medications
Drug-specific guides covering what each medication is, how its dosing is typically structured in clinical trials, and what the latest outcomes data says — without crossing into prescribing advice.
9 articles
Medications
How semaglutide dosing is typically structured
How clinicians generally think about semaglutide titration — starting low, escalating slowly, and what to discuss with your prescriber. Not a dosing instruction.
6 min · Updated 2026-05-27
Medications
How retatrutide dosing appears in clinical trials
A research-framed summary of how retatrutide has been dosed in published trials. Retatrutide is investigational and not available by prescription.
6 min · Updated 2026-05-27
Medications
Foundayo (orforglipron) is approved: what patients should know about the newest GLP-1 pill
FDA approved Foundayo (orforglipron) on April 1, 2026 — the first non-peptide oral GLP-1 with no food or water restrictions. Here's what to know before your next appointment.
5 min · Updated 2026-05-27
Medications
What the SURPASS-CVOT post-hoc analysis tells us about tirzepatide and cardiorenal outcomes
A JAMA Cardiology post-hoc analysis found tirzepatide reduced a 6-component cardiorenal endpoint by 16% vs dulaglutide over nearly 4 years. Here's what the primary vs post-hoc distinction means.
4 min · Updated 2026-05-27
Medications
GLP-1 drugs and type 1 diabetes: what a 174,000-patient study found
A JHU study of 174,678 T1D patients found GLP-1 drugs linked to 15% lower cardiovascular risk and 19% lower kidney disease risk. Here's what that means — and what it doesn't.
5 min · Updated 2026-05-27
Medications
What is semaglutide?
A plain-English explainer of semaglutide — what it is, how it works, the brand names it appears under, and what it is approved to treat.
6 min · Updated 2026-05-27
Medications
What is retatrutide?
An overview of retatrutide — an investigational triple-hormone agonist being studied for obesity and metabolic disease, and why it is not yet available by prescription.
6 min · Updated 2026-05-27
Medications
Tirzepatide explained (Mounjaro and Zepbound)
What tirzepatide is, how it differs from semaglutide, and the brand names it is sold under.
5 min · Updated 2026-05-27
Medications
CagriSema: what it is, where it stands, and what the trial data actually show
Novo Nordisk's CagriSema achieved ~23% weight loss in Phase 3 trials but failed to demonstrate non-inferiority to tirzepatide in a head-to-head test. An NDA is under FDA review. Here's what patients following the pipeline need to know.
3 min · Updated 2026-05-27